<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="combination with peginterferon and ribavirin, stratified by the presence of" exact="cirrhosis" post="and prior treatment experience. Tolerability was assessed at each"/>
 <result pre="severe adverse events leading to treatment discontinuations, hospitalizations or severe" exact="anemia" post="and a substantially higher cost per SVR when compared"/>
 <result pre="US population.[5] Untreated HCV is likely to progress to liver" exact="cirrhosis" post="and is strongly associated with the development of hepatocellular"/>
 <result pre="submitted (Clinicaltrials.gov registration: NCT02113631). Patients Patients were recruited from the" exact="hepatitis" post="C outpatient clinic. The trial was conducted as a"/>
 <result pre="GT1 infection and evidence of chronic hepatitis. The presence of" exact="cirrhosis" post="was confirmed by a liver biopsy completed within 3"/>
 <result pre="a liver biopsy was not available, a clinical assessment of" exact="cirrhosis" post="risk was performed by the two independent hepatologists (YFY"/>
 <result pre="creatinine ≤ 1.5 mg/dL; patients needed to demonstrate adequately controlled" exact="diabetes mellitus" post="and normal or adequately controlled TSH on prescription medication."/>
 <result pre="adequately controlled TSH on prescription medication. Patients with compensated liver" exact="cirrhosis" post="were eligible to participate in the study. Patients who"/>
 <result pre="4 weeks of treatment. Prior non-responders or patients with compensated" exact="cirrhosis" post="received boceprevir for 44 weeks and Peg-IFN/RBV for 48"/>
 <result pre="after 4 weeks of treatment. Non-responders and patients with compensated" exact="cirrhosis" post="were prescribed telaprevir for 12 weeks and Peg-IFN/RBV for"/>
 <result pre="early after a number of serious adverse events (in particular" exact="rash" post="with telaprevir) were increasingly reported. Resource use was prospectively"/>
 <result pre="Hispanic or Latino. Liver biopsy results revealed advanced fibrosis or" exact="cirrhosis" post="(F3 and F4) in 10/50 (20%), and 2/50 (4%)"/>
 <result pre="and F4) in 10/50 (20%), and 2/50 (4%) patients had" exact="cirrhosis" post="determined with clinical assessment by the two independent hepatologists."/>
 <result pre=" • Male 25 (100) 24 (96) Advanced fibrosis (3/4) or" exact="cirrhosis" post="[n (%)] 6 (24) 6 (24) Treatment exposure [n"/>
 <result pre="hospitalization due to progressive maculopapular rash, and another developed severe" exact="anemia" post="(Hb ≤8 g/dL). Of the two patients on boceprevir"/>
 <result pre="on boceprevir who stopped treatment early, one experienced a severe" exact="rash" post="and the other had severe dysgeusia. Four patients (3"/>
 <result pre="0.04  • Hospitalization 0 (0) 1 (4) 0.77  • Severe" exact="anemia" post="(&amp;lt;8 g/dL) 0 (0) 1 (4) 0.77  • Total"/>
 <result pre="two novel protease inhibitors in 2011 sparked an interest in" exact="hepatitis" post="C treatment. Given the lack of evidence-based guidelines concerning"/>
 <result pre="hepatitis C treatment. Given the lack of evidence-based guidelines concerning" exact="hepatitis" post="C treatment when these drugs were approved, clinicians preferred"/>
 <result pre="a third are older than 60 years. As a result," exact="hepatitis" post="C is an important disease of aging; especially since"/>
 <result pre="detect any differences among important sub-populations, such as patients with" exact="cirrhosis" post="or women. Additionally, the FDA approved two new DAAs,"/>
 <result pre="Pragmatic RCTs in the context of the newer generation of" exact="hepatitis" post="C therapies merits discussion. These newer antiviral treatments achieve"/>
 <result pre="sicker and aging population can be particularly useful in guiding" exact="hepatitis" post="C treatment choices. Based on our findings and the"/>
 <result pre="References References 1Mohd HanafiahK, GroegerJ, FlaxmanAD, WiersmaST. Global epidemiology of" exact="hepatitis" post="C virus infection: new estimates of age-specific antibody to"/>
 <result pre="Guidelines for the screening, care and treatment of persons with" exact="hepatitis" post="C infection. World Health Organization Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 3ArmstrongGL,"/>
 <result pre="http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 3ArmstrongGL, WasleyA, SimardEP, McQuillanGM, KuhnertWL, AlterMJ. The prevalence of" exact="hepatitis" post="C virus infection in the United States, 1999 through"/>
 <result pre="2006;144(10):705–14. .16702586 4DennistonMM, JilesRB, DrobeniucJ, KlevensRM, WardJW, McQuillanGM, et al.Chronic" exact="hepatitis" post="C virus infection in the United States, National Health"/>
 <result pre="5DominitzJA, BoykoEJ, KoepsellTD, HeagertyPJ, MaynardC, SporlederJL, et al.Elevated prevalence of" exact="hepatitis" post="C infection in users of United States veterans medical"/>
 <result pre="2005;41(1):88–96. 10.1002/hep.20502 .15619249 6PradatP, VoirinN, TillmannHL, ChevallierM, TrepoC. Progression to" exact="cirrhosis" post="in hepatitis C patients: an age-dependent process. Liver international:"/>
 <result pre=".15619249 6PradatP, VoirinN, TillmannHL, ChevallierM, TrepoC. Progression to cirrhosis in" exact="hepatitis" post="C patients: an age-dependent process. Liver international: official journal"/>
 <result pre="al.Hepatitis C virus infection is associated with the development of" exact="hepatocellular carcinoma." post="Proceedings of the National Academy of Sciences of the"/>
 <result pre="Falck-YtterY, HoltzmanD, TeoCG, et al.Recommendations for the identification of chronic" exact="hepatitis" post="C virus infection among persons born during 1945–1965. MMWR"/>
 <result pre="risk of long-term morbidity and mortality in patients with chronic" exact="hepatitis" post="C: results from an analysis of data from a"/>
 <result pre="or in combination with ribavirin as initial treatment for chronic" exact="hepatitis" post="C. Hepatitis Interventional Therapy Group. The New England journal"/>
 <result pre="placebo for 48 weeks for treatment of chronic infection with" exact="hepatitis" post="C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet."/>
 <result pre="HeathcoteEJ, LaiMY, GaneE, et al.Peginterferon alfa-2a in patients with chronic" exact="hepatitis" post="C. The New England journal of medicine. 2000;343(23):1666–72. 10.1056/NEJM200012073432301"/>
 <result pre="McCulloughAJ. Surprisingly small effect of antiviral treatment in patients with" exact="hepatitis" post="C. Annals of internal medicine. 2002;136(4):288–92. .11848726 14BrokJ, GluudLL,"/>
 <result pre="14BrokJ, GluudLL, GluudC. Ribavirin plus interferon versus interferon for chronic" exact="hepatitis" post="C. The Cochrane database of systematic reviews. 2010;(1):CD00544510.1002/14651858.CD005445.pub2 .20091577"/>
 <result pre="Di BisceglieAM, ReddyKR, BzowejNH, et al.Telaprevir for previously untreated chronic" exact="hepatitis" post="C virus infection. The New England journal of medicine."/>
 <result pre="al.Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated" exact="hepatitis" post="C virus patients. World journal of hepatology. 2014;6(9):660–9. 10.4254/wjh.v6.i9.66025276282"/>
 <result pre="KowdleyKV, ZeuzemS, AgarwalK, et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for" exact="hepatitis" post="C with cirrhosis. N Engl J Med. 2014;370(21):1973–82. 10.1056/NEJMoa1402869"/>
 <result pre="et al.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for" exact="hepatitis" post="C in patients co-infected with HIV-1: a randomized trial."/>
 <result pre="30http://www.hepatitisc.uw.edu/page/treatment/drugs/ledipasvir-sofosbuvir. 31ChhatwalJ, KanwalF, RobertsMS, DunnMA. Cost-effectiveness and budget impact of" exact="hepatitis" post="C virus treatment with sofosbuvir and ledipasvir in the"/>
</results>
